“Pembrolizumab in PD-L1-Positive Advanced Non-Small Cell Lung Carcinoma: A Meta-Analysis of Survival Benefits and Immune-Related Toxicity Events Patterns: Original Scientific Article”. ADMET and DMPK 13, no. 5 (October 14, 2025). Accessed July 12, 2026. https://pub.iapchem.org/ojs/index.php/admet/article/view/2956.